Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/23987
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2022-01-11T07:27:22Z-
dc.date.available2022-01-11T07:27:22Z-
dc.date.issued2009-07-
dc.identifier.citationGören, B. vd. (2009). "Investigation of neuroprotective effects of cyclooxygenase inhibitors in the 6-hydroxydopamine induced rat Parkinson model". Turkish Neurosurgery, 19(3), 230-236.tr_TR
dc.identifier.issn1019-5149-
dc.identifier.urihttp://hdl.handle.net/11452/23987-
dc.description.abstractAIM: Recent experimental and clinical studies on Parkinson's disease point out the pivotal role of inflammation in the pathogenesis of neurodegeneration and the possible positive effects of nonsteroidal anti-inflammatory drug therapies. Our aim in this study was to investigate the preventive effects of nonsteroidal anti-inflammatory drugs in the 6-hydroxydopamine (6-OHDA) induced rat model of Parkinson's disease. MATERIAL and METHODS: Twenty-one female Wistar-Albino rats (200-250g) were used in this study. The rats were divided in three groups: Saline group (n: 7, 2 ml), Acetylsalicylic acid group (n: 7, 100 mg/kg), and Meloxicam group (n: 7, 50 mg/kg). An hour after administration, the rats received a unilateral intranigral injection of 6-OHDA to produce the Parkinson model lesion. Rotational tests were performed two weeks later as follow-up. Immunohistochemical tests were performed in all groups to determine the severity of the lesion in the substantia nigra. RESULTS: Administration of drugs an hour before the lesions were created did not protect the degeneration of dopaminergic neurons in the substantia nigra. CONCLUSION: Oral usage of low repeated doses of nonsteroidal anfi-inflammatory drugs may possibly slow down the progression of the disease.en_US
dc.language.isoenen_US
dc.publisherTürk Nöroşurji Derneğitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject6-OHDAen_US
dc.subjectNSAIDen_US
dc.subjectParkinson modelen_US
dc.subjectRaten_US
dc.subjectInduced dopaminergic neurotoxicityen_US
dc.subjectIn-vivo microdialysisen_US
dc.subjectMptp-mouse modelen_US
dc.subjectNf-kappa-ben_US
dc.subjectSodium-salicylateen_US
dc.subjectAntiinflammatory drugsen_US
dc.subject7-nitroindazole protectsen_US
dc.subjectInduced degenerationen_US
dc.subjectDiseaseen_US
dc.subjectAspirinen_US
dc.subjectNeurosciences & neurologyen_US
dc.subjectSurgeryen_US
dc.subject.meshAmphetaminesen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntiparkinson agentsen_US
dc.subject.meshApomorphineen_US
dc.subject.meshAspirinen_US
dc.subject.meshBehavior, animalen_US
dc.subject.meshCyclooxygenase inhibitorsen_US
dc.subject.meshDisease models, animalen_US
dc.subject.meshFemaleen_US
dc.subject.meshImmunohistochemistryen_US
dc.subject.meshNeuroprotective agentsen_US
dc.subject.meshOxidopamineen_US
dc.subject.meshParkinsonian disordersen_US
dc.subject.meshRatsen_US
dc.subject.meshRats, wistaren_US
dc.subject.meshSympatholyticsen_US
dc.subject.meshThiazinesen_US
dc.subject.meshThiazolesen_US
dc.titleInvestigation of neuroprotective effects of cyclooxygenase inhibitors in the 6-hydroxydopamine induced rat Parkinson modelen_US
dc.typeArticleen_US
dc.identifier.wos000268455100004tr_TR
dc.identifier.scopus2-s2.0-70349910574tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Fizyoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Histoloji ve Embriyoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nöroşirürji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0001-5757-8450tr_TR
dc.identifier.startpage230tr_TR
dc.identifier.endpage236tr_TR
dc.identifier.volume19tr_TR
dc.identifier.issue3tr_TR
dc.relation.journalTurkish Neurosurgeryen_US
dc.contributor.buuauthorGören, Bülent-
dc.contributor.buuauthorMimbay, Zehra-
dc.contributor.buuauthorBilici, Nebahat-
dc.contributor.buuauthorZarifoğlu, Mehmet-
dc.contributor.buuauthorOğul, Erhan-
dc.contributor.buuauthorKorfalı, Ender-
dc.contributor.researcheridAAH-1718-2021tr_TR
dc.contributor.researcheridABC-1475-2020tr_TR
dc.indexed.trdizinTrDizintr_TR
dc.identifier.pubmed19621286tr_TR
dc.subject.wosClinical neurologyen_US
dc.subject.wosSurgeryen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubmeden_US
dc.wos.quartileQ4en_US
dc.contributor.scopusid6602543716tr_TR
dc.contributor.scopusid35092977400tr_TR
dc.contributor.scopusid35092119200tr_TR
dc.contributor.scopusid6603411305tr_TR
dc.contributor.scopusid6603268541tr_TR
dc.contributor.scopusid7004641343tr_TR
dc.subject.scopusDopaminergic Nerve Cell; Parkinson's Disease; Microgliaen_US
dc.subject.emtreeAcetylsalicylic aciden_US
dc.subject.emtreeAdrenergic receptor blocking agenten_US
dc.subject.emtreeAmphetamine derivativeen_US
dc.subject.emtreeAntiparkinson agenten_US
dc.subject.emtreeApomorphineen_US
dc.subject.emtreeMeloxicamen_US
dc.subject.emtreeNeuroprotective agenten_US
dc.subject.emtreeOxidopamineen_US
dc.subject.emtreeProstaglandin synthase inhibitoren_US
dc.subject.emtreeThiazole derivativeen_US
dc.subject.emtreeThiazole derivativeen_US
dc.subject.emtreeAnimalen_US
dc.subject.emtreeAnimal behavioren_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeChemically induced disorderen_US
dc.subject.emtreeDisease modelen_US
dc.subject.emtreeDrug effecten_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeImmunohistochemistryen_US
dc.subject.emtreeParkinsonismen_US
dc.subject.emtreePathologyen_US
dc.subject.emtreeRaten_US
dc.subject.emtreeWistar raten_US
Appears in Collections:Scopus
TrDizin
Web of Science

Files in This Item:
File Description SizeFormat 
Gören_vd_2009.pdf223.99 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons